Brief: Celyad: Updates on CYAD-01 Produced with OptimAb Manufacturing Process

Celyad Oncology SA

04/09/2019 06:07

Sept 4 (Reuters) - CELYAD SA  CYAD.BR :
    * CELYAD SUCCESSFULLY DOSES FIRST PATIENT WITH CYAD-01
PRODUCED
WITH OPTIMAB MANUFACTURING PROCESS
    * TODAY ANNOUNCED SUCCESSFUL ADMINISTRATION OF CYAD-01
PRODUCED
WITH OPTIMAB MANUFACTURING PROCESS TO A PATIENT ENROLLED IN
COHORT 3 (300 MILLION CELLS) OF PHASE 1 DEPLETHINK TRIAL
    * OPTIMAB MANUFACTURING PROCESS HAS SHOWN EXCITING ACTIVITY
IN
PRECLINICAL MODELS - COO
    * WE LOOK FORWARD TO REPORTING PRELIMINARY DATA FROM
PATIENTS
ENROLLED IN DEPLETHINK TRIAL TREATED WITH CYAD-01 PRODUCED WITH
OPTIMAB PROCESS BY END OF YEAR

Source text for Eikon:  ID:nGNX29Nvk8 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))